Alida Biosciences today announced the launch of its EpiPlex™ Tri-Mod™ Service, enabling simultaneous detection and quantification of three key mRNA modifications—N6-methyladenosine (m6A), inosine, and ...

Alida Biosciences today announced the launch of its EpiPlextm Tri-Modtm Service, enabling simultaneous detection and quantification of three key mRNA modifications?N6-methyladenosine (m6A), inosine, ...

Moderna (MRNA) ended the recent trading session at $51.30, demonstrating a -1.54% change from the preceding day's closing price. This change lagged the S&P 500's 0.62% gain on the day. Meanwhile, the ...

Moderna (MRNA) closed at $54.26 in the latest trading session, marking a +2.69% move from the prior day. This change outpaced the S&P 500's 0.8% gain on the day. Meanwhile, the Dow lost 0.15%, and the ...

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications; First-in-class METTL3 inhibitor reprograms malignant progenitor cells by modu ...

STORM Therapeutics raises $56M Series C and doses first patient in Phase 2 sarcoma trial of STC-15, the world’s first RNA ...

A nanodisc platform that offers a clearer view of how key viral proteins interact with antibodies could lead to better HIV ...

Eye.ai, a pioneer in integrated optical interconnects, today announced it has raised $80 million in Series C financing led by Sutter Hill Ventures with participation from existing investors including ...

Storm Therapeutics raises $56M in Series C funding to accelerate cancer therapy development and expand its innovative ...

STORM Therapeutics, a Cambridge-based clinical stage company targeting RNA modifications to reprogram cells and develop novel ...

Explore how advances in accuracy, throughput and cost are making long-read sequencing more accessible at scale.

Since 2007, Jezebel has been the Internet's most treasured source for everything celebrities, sex, and politics...with teeth.